Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX

Key Points

• Blue Owl Capital Holdings acquired 437,552 shares of Immix Biopharma worth approximately $4.51 million, representing about 0.80% of the company and 0.7% of Blue Owl’s portfolio.
• Analyst sentiment remains broadly positive, with eight Buy ratings, one Hold, and one Sell; the consensus rating is “Moderate Buy” with a target price of $21.29.
• Immix Biopharma shares opened at $13.16, near their 12-month high of $13.20, despite the company reporting a quarterly loss of $0.18 per share that narrowly missed estimates.

Blue Owl Capital Holdings LP acquired a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 437,552 shares of the company's stock, valued at approximately $4,511,000. Immix Biopharma makes up approximately 0.7% of Blue Owl Capital Holdings LP's portfolio, making the stock its 24th largest position. Blue Owl Capital Holdings LP owned approximately 0.80% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Allworth Financial LP acquired a new stake in Immix Biopharma during the fourth quarter worth approximately $30,000. Mathes Company Inc. acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $56,000. Balyasny Asset Management L.P. acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $67,000. Kera Capital Partners Inc. bought a new position in shares of Immix Biopharma during the 4th quarter worth approximately $68,000. Finally, Velan Capital Investment Management LP boosted its holdings in shares of Immix Biopharma by 40.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company's stock worth $73,000 after buying an additional 10,000 shares in the last quarter. 11.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IMMX. Lifesci Capital began coverage on shares of Immix Biopharma in a research report on Wednesday, June 17th. They set an "outperform" rating and a $19.00 price objective for the company. Citigroup reiterated a "market outperform" rating on shares of Immix Biopharma in a research report on Friday, August 14th. Needham & Company LLC started coverage on shares of Immix Biopharma in a research note on Wednesday, July 22nd. They set a "buy" rating and a $21.00 target price on the stock. Morgan Stanley reduced their price target on shares of Immix Biopharma from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Finally, HC Wainwright lifted their price target on shares of Immix Biopharma from $20.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.29.

Immix Biopharma Trading Down 0.2%

Shares of IMMX stock opened at $13.16 on Friday. The firm has a market capitalization of $941.47 million, a PE ratio of -14.95 and a beta of 0.11. The firm has a fifty day simple moving average of $9.98 and a two-hundred day simple moving average of $9.24. Immix Biopharma, Inc. has a 12 month low of $1.94 and a 12 month high of $13.20.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). On average, equities analysts predict that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.

About Immix Biopharma

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source